Kamada Ltd. (NASDAQ:KMDA – Get Free Report) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 13,300 shares, a decrease of 68.6% from the August 15th total of 42,300 shares. Based on an average daily trading volume, of 27,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Several analysts have issued reports on KMDA shares. StockNews.com raised shares of Kamada from a “hold” rating to a “buy” rating in a report on Wednesday, August 30th. TheStreet raised shares of Kamada from a “d+” rating to a “c-” rating in a report on Thursday, August 24th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a research note on Thursday, August 17th.
Institutional Investors Weigh In On Kamada
Kamada Stock Performance
NASDAQ:KMDA opened at $5.15 on Thursday. The company has a quick ratio of 0.75, a current ratio of 1.97 and a debt-to-equity ratio of 0.06. The company has a market cap of $230.82 million, a P/E ratio of 64.38 and a beta of 0.94. Kamada has a fifty-two week low of $3.72 and a fifty-two week high of $5.85. The firm’s 50 day moving average is $5.25 and its two-hundred day moving average is $4.95.
Kamada (NASDAQ:KMDA – Get Free Report) last released its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. Kamada had a net margin of 2.35% and a return on equity of 7.42%. The company had revenue of $37.44 million during the quarter, compared to analyst estimates of $34.18 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. Analysts expect that Kamada will post 0.06 EPS for the current year.
Kamada Company Profile
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.
- Five stocks we like better than Kamada
- The How and Why of Investing in Biotech Stocks
- Is Enbridge Stock Too Cheap to Pass Up Now?
- How to Invest in the Healthcare Sector
- 5 Best REIT Alternatives for Passive Real Estate Income
- 5 Top Rated Dividend Stocks to Consider
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.